@col69 to briefly summarise an earlier and lengthy post of mine, I personally think DEP-Docetaxel is/will be a dud and not guaranteed to get partnered.
The limited patent life (primarily until 2032 with potential extension up to 5 years but not guaranteed) is going to be an issue IMO.
My estimated timelines (if partnered):
2023: Partner signed to take DEP-Docetaxel into a Phase 3 trial.
2023/2024: Phase 3 trial commences
2026/2027: Phase 3 trial complete
2027: Full results read out.
2028: If trial successful, one full year for NDA submission and possible FDA approval.
2029: Potential first sales of DEP-Docetaxel.
However, given the primary and guaranteed patent coverage runs out in 2032 I have serious doubts that Starpharma will be able to sign a partner with a meaningful deal in the first place to actually take the drug into Phase 3. Not with such little guaranteed patent protection of only 3 years.
DYOR
P.S. Better patent life on the other two internal DEP candidates
- Forums
- ASX - By Stock
- SPL
- Ann: VIRALEZE relaunched by LloydsPharmacy in the UK
Ann: VIRALEZE relaunched by LloydsPharmacy in the UK, page-74
-
- There are more pages in this discussion • 180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.90M |
Open | High | Low | Value | Volume |
10.0¢ | 10.0¢ | 9.7¢ | $38.11K | 389.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20455 | 9.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 38876 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20455 | 0.097 |
1 | 100000 | 0.096 |
2 | 60526 | 0.095 |
1 | 10000 | 0.094 |
2 | 134306 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.100 | 38876 | 3 |
0.105 | 199768 | 2 |
0.110 | 226808 | 10 |
0.115 | 85453 | 2 |
0.120 | 79405 | 9 |
Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |